The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1157
May 26, 2003
View Complete Issue         Table of Contents 2019 
Ophthalmic Cyclosporine (Restasis) for Dry Eyes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ophthalmic Cyclosporine (Restasis) for Dry Eyes
May 26, 2003 (Issue: 1157)
A cyclosporine 0.05% ophthalmic emulsion (Restasis - Allergan) has been approved by the FDA for use in patients with dry eye disease (keratoconjunctivitis sicca). This review begins with a discussion of the causes of dry eye disease and includes...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ophthalmic Cyclosporine (Restasis) for Dry Eyes
Article code: 1157b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.